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Cancer growtha b s t r a c t
Pancreatic ductal adenocarcinoma (PDAC) ranks fourth on the list of cancer-related causes of death.
Deregulation or dysfunction of miRNAs contribute to cancer development. In this study, we found
that low miR-545 level and high RIG-I protein in PDAC tissues were both correlated with low
survival rate. MiR-545 up-regulation inhibited PDAC cell lines growth and vice versa. 30UTR of
RIG-I was targeted by miR-545. Thus we concluded that low miR-545 levels in PDAC promote tumor
cells growth, and this is associated with reduced survival in PDAC patients. MiR-545 exerts its effects
by directly targeting RIG-1.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) ranked 13th in the
list of most commonly diagnosed cancers and was the ﬁfth most
common cause of cancer death in China in 2006 [1]. Due to the
asymptomatic onset of pancreatic cancer, most patients are in
advanced or metastatic condition at the time of diagnosis, resulting
in poor prognosis. Surgical resection, is currently the only chance
for cure, improving ﬁve-year survival rates from <4% if left
untreated to 25–30% after resection [2–4]. Advances in chemo-
radiation therapy have been slow over the last few decades. To
develop effective treatments, a better understanding of the
molecular mechanism of PDAC is urgently needed. Accumulating
data has showed that microRNAs (miRNAs) were involved in the
pathogenesis of PDAC.
MicroRNAs (miRNAs) is a class of small RNAs approximately
18–22 nucleotides in length. MiRNAs suppress protein expression
by inhibiting translation or inducing mRNA degradation by binding
to the 30-untranslational region (30UTR) of target mRNAs [5].Deregulation or dysfunction of miRNAs contribute to cancer devel-
opment [5–10]. MiRNAs was also involved in the pathogenesis of
PDAC. For example, the miR-200 family appear to have important
roles in PDAC and has been shown to regulate epithelial to
mesenchymal transition by targeting ZEB1 and SIP1 [11,12]. The
role of miR-545 has previously been studied in lung cancer. It
has been found to suppress cell proliferation both in vitro and
in vivo; miR-545 caused cell cycle arrest at the G0/G1 phase and
induced cell apoptosis in lung cancer cells by targeting cyclin D1
and CDK4 genes [13].
Here we investigated the role of miR-545 in PDAC. We found
low miR-545 level in PDAC tissues were correlated reduced low
patients survival rate. We then investigated the role of miR-545
in PDAC cell lines by loss and gain-of-function approaches. The
predicted targeted genes of miR-545 were also considered and val-
idated. Our data helps to elucidate the role of miR-545 in PDAC.
2. Materials and methods
2.1. Patients
Surgical specimens from 78 PDAC patients and matched tumor-
adjacent normal tissues were obtained postoperatively in 2009
from Department of General Surgery, Changhai Hospital, Second
Military Medical University (Shanghai, China). All patients gave
signed, informed consent for their tissues to be used for scientiﬁc
Fig. 1. Low miR-545 level in PDAC tissues was correlated with low survival rate. The miR-545 expression in 78 pairs PDAC and in matched tumor-adjacent normal tissues
were assayed by RT-PCR. The difference of miR-545 expression between PDAC and in matched tumor-adjacent normal tissues were compared (A). The miR-545 expression in
78 pairs PDAC and matched tumor-adjacent normal tissues (B). The Kaplan–Meier plot of overall survival in PDAC patients post-operation according the expression of miR-
545. The miR-545 level was assessed by qRT-PCR, and its median value of all 78 cases was chosen as the cutoff point for separating miR-545 high expression tumors from
miR-545 low expression case. The median overall survival is 26 months. At the end of follow up, in the miR-545 high expression group, there were 17 survival patients, in the
miR-545 high expression group, there were 8 survival patients.(C). All RT-PCR experiment were performed for three time, All data are mean ± S.D. of three separate
experiments. ⁄P < 0.05.
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Changhai Hospital, Second Military Medical University (Shanghai,
China). All diagnoses were based on pathological and/or cytological
evidence. The histological features of the specimens were
evaluated by senior pathologists according to the World Health
Organization classiﬁcation criteria. Tissues were obtained before
chemotherapy and radiotherapy and were immediately frozen
and stored at 80 C prior to qRT-PCR assay. 78 patients had been
followed-up for 3 years and complete clinical data were electroni-
cally recorded.
2.2. Cell culture
HEK293, PANC1, SW1990 cell lines were obtained from the Cell
Bank of Chinese Academy of Science (Shanghai, China) and main-
tained in DMEM medium (Hyclone, South Logan, UT, USA) supple-
mented with 10% fetal bovine serum (Hyclone), 2 mM L-glutamine
and 100 lg/mL penicillin/streptomycin (Bio Light, Shanghai, China)
as described in previous studies [14–16].
2.3. Real time q-PCR
Real-time quantitative PCR analysis for miR-545 was performed
by Shengong Company (Shanghai) using standard protocols on an
Applied Biosystem’s 7500 HT sequence Detection System. miR-
545 expression was assessed using a mirVana™ qRT-PCR miRNADetection Kit (Ambion, USA). The primers were designed and
synthesized by Shengong Company (Shanghai). U6 as a internal
control.
2.4. MTT assay
For MTT assay, 5  103 cells per well were seeded in triplicate in
a 96-well plate with complete growth medium. Cells viability was
measured over 5 days using the MTT assay (Promega, Fitchburg,
WI, USA) as described previously [8,17–19]. The data was mea-
sured by Microtiter plate reader 570-nm ﬁlters (Promega, USA).
2.5. MicroRNAs targets prediction
TargetScanHuman (http://www.targetscan.org/vert_61/)
[20–23] is applied to identify the potential target of miR-545.
2.6. MiRNAs antisense, miRNAs mimics, oligonucleotides
MiRNAs mimics (miR-545 mimics) and miRNAs antisense oligo-
nucleotides (miR-545-ASO) were obtained from GenePharma
(GenePharma, China). MiRNAs ASO, MiRNAs mimics, negative con-
trol (NC) were transfected into cells at a concentration of 50 nM
using Lipofectamine 2000 (Invitrogen, Canada) transfection
reagent according to the manufacturer’s instructions. 48 h later
cells were collected for further experiments.
Fig. 2. miR-545 mimics transfection inhibited PDAC cell lines growth and induce cells apoptosis. MiR-545 levels in normal pancreas, PANC1, SW1990 and HEK293 cell lines
were assayed by RT-PCR. The miR-545 expression in normal pancreas tissue was arbitrarily deﬁned as 100% (A). 48 h after miR-545 mimics transfection, the level of miR-545
in PANC1, SW1990 cell lines were assayed by RT-PCR. The control group was arbitrarily deﬁned as 100% (B). 48 h after miR-545 mimics transfection, PANC1 and SW1990
proliferation were assayed by MTT at the indicted time point; two-tailed Student’s t test was used to assay the difference between proliferation at 72 h (C). All data are
mean ± S.D. of three separate experiments. ⁄P < 0.05.
Fig. 3. miR-545 mimics transfection promoted PDAC cell lines growth and inhibited cell apoptosis. HEK293, PANC1 and SW1990 cell lines were transfected with miR-545
ASO. 48 h later miR-545 levels in HEK293, PANC1 and SW1990 cell lines were assayed by RT-PCR. MiR-545 levels in blank control was arbitrarily deﬁned as 100% (A). 48 h
after miR-545 ASO transfection, HEK293, PANC1 and SW1990 cell lines proliferation were assayed by MTT at the indicted time points. two-tailed Student’s t test was used to
assay the difference between proliferation at 72 h (B). All data are mean ± S.D. of three separate experiments. ⁄P < 0.05.
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The RIG-I 30UTR reporter plasmids (pRL-RIG-I) were constructed
by Shengong Company (Shanghai). Mutation in the miR-545 seed
regions of the RIG-I 30UTR was generated by using QuikChang
Multi site -directed mutagenesis kit (Stratagene). RL reporter
plasmids (3.6 fmol) and pGL3-control (500 ng for normalization;
Promega) were transfected with Lipofectamine 2000 (Invitrogen)
into HEK293 (6  104 cells per well). Cells were collected after
48 h for assay using the Dual Luciferase reporter assay system
(Promega) [24].2.8. Immunohistochemistry
Brieﬂy, 4-lm thick sections were cut and anti-RIG-I antibody
(Sigma–Aldrich) was applied. Subsequent counterstaining was per-
formed with hematoxylin. Immunostaining results for RIG-I were
evaluated using a semi-quantitative scoring system as described
previously [25], which calculated the staining intensity and the
percentage of positive cells. Immunohistochemistry (IHC) staining
was scored according to the following criteria: , 0–10% of the
nucleated cells stained, +, 10–40% stained, ++; 40–70% stained
and +++, 70–100% stained. RIG-I expression was considered to be
Fig. 4. Target genes of miR-545 were predicted and conﬁrmed. Putative targeted genes were predicted by TargetScanHuman, the binding site of putative targeted gene, and
mutated site of miR-545 were shown (A). The RL reporter plasmids (RL-control, RL-RIG-I, RL-mutated RIG-I) and miR-545 or miR-NC were co-transfected into HEK293 cells,
along with a ﬁreﬂy luciferase reporter (pGL control) for normalization. Luciferase activities were measured after 48 h. Then the ratio of RL activity of ﬁreﬂy luciferase activity
in miR-545 treated group were calculated and compared with the ratio in miR-NC group (which was arbitrarily deﬁned as 100%) (B). All data are mean ± S.D. of three separate
experiments. ⁄P < 0.05.
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sion was (  +) and (++  +++), which represented low and high
expression, respectively.
2.9. RIG-I mRNA expression in PDAC analysis
The data of RIG-I mRNA in PDAC was queried from Gene
Expression Omnibus.
2.10. Statistical Analysis
Data was presented as the mean ± S.D from at least three
independent experiments. The difference between groups were
analyzed using two-tailed Student’s t test when only two groups
were compared. The Wilcoxon matched-pairs signed rank test
was used to determine if there was a statistically signiﬁcant differ-
ence in the expression of miR-545 and RIG-I between matched
pairs. The difference between groups were analyzed using ANOVA
when three or more than three groups were compared. Correlationanalysis was performed by two-tailed Person’s correlation coefﬁ-
cient analysis. Patients survival was determined by Kaplan–Meier
analysis. Statistical analyses were performed using SPSS software
(version 17.0). P < 0.05 was considered signiﬁcantly different.
3. Results
3.1. Low miR-545 level in PDAC tissues was correlated with low
survival rate
78 pairs of PDAC tissues and matched tumor-adjacent normal
tissues were collected. MiR-545 level was assayed by RT-PCR, data
were normalized by U6 small nuclear RNA level. We found that 63
of 78 pairs showed a lower miR-545 level in PDAC tissues than in
matched tumor-adjacent normal tissues (Fig. 1A). Fig. 1B showed
miR-545 level in tumor tissues and normal tissues separately. To
investigate whether down-regulation of miR-545 in PDAC tissues
was correlated with prognosis of PDAC patients, Tumor tissues of
78 PDAC patients who had undergone tumor resection were
Fig. 5. High RIG- I protein level in PDAC tissues was correlated with low survival rate. RIG-I protein levels in 78 pairs of PDAC tissues and matched tumor-adjacent normal
tissues were assayed by IHC. 12 representative cases were shown. RIG-I located in cytoplasmic; the RIG-I expression was scored (A). RIG-I protein levels in 78 pairs of PDAC
tissues and matched tumor-adjacent normal tissues were compared (B). The mean level of RIG-I in the 78 pairs (C). RIG-I expression in PDAC tissues were higher than in
adjacent normal tissue (GSE15471) (D). Kaplan–Meier plot of overall survival in PDAC patients post-operation according the expression of RIG-I (E). All data are mean ± S.D. of
three separate experiments. ⁄P < 0.05.
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Kaplan–Meier method revealed that lower miR-545 expression
levels in PDAC tissues was signiﬁcantly correlated with reduced
disease-free survival of PDAC patient (P = 0.0112).
3.2. MiR-545 up-regulation inhibited PDAC cell lines growth
Next we investigated the role of miR-545 in PDAC cell lines.
Firstly, we measured the miR-545 level in HEK293, PANC1,
SW1990 cell lines and normal pancreas tissues. We found the level
ofmiR-545 in PDAC cell lineswas lower than in normal pancreas tis-
sues and HEK293 (Fig. 2A). Next we up-regulated the level of miR-
545 by miR-545 mimics transfection in PANC1 and SW1990 cell
lines. The effectiveness of transfection was veriﬁed by
RT-PCR (Fig. 2B). 48 h after mimics transfection, cellular prolifera-
tionwas assayed byMTT. Data revealed thatmiR-545mimics trans-
fection inhibited PANC1 and SW1990 cell lines growth (Fig. 2C).
3.3. MiR-545 down-regulation promoted PDAC cell lines growth
Next we down-regulated the level of miR-545 by miR-545 ASO
transfection in PANC1,SW1990 and HEK293 cell lines. We found
miR-545 ASO transfection down-regulated the miR-545 level in
the three cell lines. As PANC1,SW1990 cell lines showed a low level
of miR-545, miR-545 ASO transfection did not show a dramatic
effect (Fig. 3A). Then cells proliferation was assayed by MTT assay.We found miR-545 ASO transfection promoted cells growth in
PANC1, SW1990 and HEK293 (Fig. 3B).
3.4. RIG-I was targeted by miR-545
To explore the potential target gene of miR-545, we applied
bioinformatics algorithms to predict. Many genes were predicted
(data not shown), including retinoic acid-inducible gene 1 (RIG-I)
(DDX58) (Fig. 4A). RIG-I and Toll like receptors are the key innate
immune pattern recognition receptors and are tightly regulated
by elaborate mechanism to ensure a beneﬁcial outcome in
response to foreign invaders. RIG-I was chosen for further investi-
gation, and the binding site and mutated sites in RIG-I were shown
in Fig. 4A. 30UTR and its mutated version of RIG-I were cloned into
luciferase reporter plasmids. MiR-545 and the reporter plasmids
were co-transfected into HEK293 cells. We found that in wild type
30UTR, miR-545 reduced the luciferase activity, while in the three
mutated version, the difference between miR-NC and miR-545
was not signiﬁcant (Fig. 4B). These data indicated that RIG-I was
targeted by miR-545.
3.5. High RIG-I protein level in PDAC tissues was correlated with low
survival rate
To conﬁrm the role of RIG-I in PDAC. We examined the RIG-I
level in 78 PDAC tissues and matched tumor-adjacent normal
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showed great higher RIG-I expression (Fig. 5A). The RIG-I
expression was scored, in 78 pairs of PDAC tissues and matched
tumor-adjacent normal tissues, there were 54 of 78 pairs with
higher RIG-I level in PDAC tissues than in normal control
(Fig. 5B). Then we calculated the mean expression of RIG-I in
the 78 PDAC tissues, and found the mean expression of RIG-I in
78 PDAC tissues was higher than the matched tumor-adjacent
normal tissues (Fig. 5C). Next we explored Gene Expression Omni-
bus (GEO) for analysis of RIG-I mRNA expression in PDAC. We
found RIG-I expression in tumor tissues was higher than in adja-
cent normal tissues (P = 1.435  107) (Fig. 5D). To evaluate the
clinical signiﬁcance of RIG-I over-expression in PDAC, we investi-
gated whether the levels of RIG-I expression were associated with
overall survival in PDAC. 78 PDAC patients were follow-up for
50 months. Kaplan–Meier curves indicated that patients with high
RIG-I expression had a signiﬁcantly shorter overall survival
(P = 0.0039) than those with low RIG-I expression. The median
value of all 78 case was chosen as the cutoff point for separating
RIG-I high expression cases from RIG-I low expression cases
(Fig. 5E).
4. Discussion
In this study, we found that low miR-545 level and high RIG-I
protein in PDAC tissues were both correlated with low survival
rate. MiR-545 up-regulation inhibited PDAC cell lines growth and
vice versa. 30UTR of RIG-I was targeted by miR-545. Thus we con-
cluded that low miR-545 level in PDAC promoted tumor cells
growth, which contributing the low PDAC patients survival rate,
and miR-545 exerted it’s role by targeting RIG-I.
In our study, we found Low miR-545 level in PDAC tissues was
correlated with low survival rate, thus miR-545 can be a role as a
prognostic marker in PDAC. In our opinion, our data may add a
new maker in microRNAs molecular proﬁles associated with
overall survival in PDAC patients [26,27].
Previous investigation revealed that cyclin D1 and CDK4 genes
are direct targets of miR-545 in lung cancer. MiR-545 inhibits
cyclin D1 and CDK4 gene expression by recognizing sequences in
their 30UTRs [13]. We also proved that the role of CDK4 in PDAC
was similar with its role in lung cancer (data not shown). Here
we focused on the role of RIG-I in PDAC.
It has been well accepted that RIG-I was an intracellular viral
RNA sensor and that its activation can initiate host innate immune
response, especially type I IFN production, to eliminate viral infec-
tion [28–31]. Recent investigation of RIG-I in cancer also reported
that RIG-I activation by its ligand pppRNA could induce apoptosis
in melanoma cells and ovarian cancer cells [32,33], Another study
showed than RIG-I was signiﬁcantly down regulated in hepatocel-
lular carcinoma (HCC). Patients with low RIG-I expression had
shorter survival and poorer response to IFN-a therapy. RIG-I
enhances IFN-a response by amplifying IFN-a effector signaling
via strengthening STAT1 activation [34].
In our study, we found that high RIG-I protein level in PDAC
tissues was correlated with shorter survival. This discrepancy is
very interesting. In HCC, IFN-a may be important in the preven-
tion of HCC carcinogenesis and that low expression of RIG-I may
impair cellular response to IFN-a, promoting HCC carcinogenesis.
In PDAC, IFN-a may be not involve in the pathogenesis of PDAC,
and the mechanism of RIG-I in PDAC needed further
investigation.
In conclusion, we found low miR-545 level and high RIG-I level
in PDAC growth, which contributing the low PDAC patients sur-
vival rate. miR-545 exerted it’s role by targeting RIG-I. We hoped
our study might provide some hint for further studies.Conﬂict of interest
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